Clinical trial · Observational
Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer
Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer: Molecular Characterization and Implications for Therapeutic Strategies
NCT01577511CI-TRIAL-00097512completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of this study is to identify and characterize subpopulations of cells with invasive capacity in colorectal cancer from primary tumor, blood and metastatic samples.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Neoplasms | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Samples and follow up | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 30 Patients
- description
- Patients with operable, stage III or IV, adenocarcino-type colorectal cancer treated at the Nîmes University Hospital. Intervention: Samples and follow up
- interventionNames
- Biological: Samples and follow up
Primary outcomes (1)
- measure
- Ability to maintain the cells isolated from colorectal tumors in culture or 3D collagen matrices and then infect these cells to make them express reporter genes: yes/no.
- timeFrame
- Baseline (Day 0)
Secondary outcomes (21)
- measure
- Serology HIV
- timeFrame
- baseline; day 0
- measure
- Serology Hepatitis B
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * The patient must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * Patient with adenocarcinoma-type colorectal cancer: * stage III at diagnosis, surgical resection of the primary tumor proposed. * stage IV at diagnosis, surgical resection of the primary tumor and possibly of metastases proposed. * Stage IV who have already undergone surgical excision of the primary tumor, and for whom metastasectomy is now proposed. Exclusion Criteria: * The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * Patients for whom surgical resection of the primary tumor is not considered as an option * PStage IV at diagnosis, but metastasectomy is not considered as an option * Patients with positive HIV, Hepatitis B or Hepatitis C serology
References
Publications (1)
- RESULTGrillet F, Bayet E, Villeronce O, Zappia L, Lagerqvist EL, Lunke S, Charafe-Jauffret E, Pham K, Molck C, Rolland N, Bourgaux JF, Prudhomme M, Philippe C, Bravo S, Boyer JC, Canterel-Thouennon L, Taylor GR, Hsu A, Pascussi JM, Hollande F, Pannequin J. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture. Gut. 2017 Oct;66(10):1802-1810. doi: 10.1136/gutjnl-2016-311447. Epub 2016 Jul 25. PMID 27456153